Access cutting-edge multiple myeloma treatment through this clinical trial at a research site in Greeley. Study-provided care at no cost to qualified participants.
Access multiple myeloma specialists in Greeley at no cost
This study follows strict safety protocols and ethical guidelines
All study-related multiple myeloma treatment provided free
The purpose of this clinical trial is to (1) learn whether the BCMA-CD3 bispecific antibody elranatamab can provide more benefit to people with multiple myeloma compared to a combination therapy including daratumumab, pomalidomide, and dexamethasone, and (2) learn about the safety and activity of elranatamab in combination with the anti-CD38 monoclonal antibody daratumumab. People with multiple myeloma who have received previous treatment including lenalidomide will be enrolled in the study. Pa
Sponsor: Pfizer
Check if you qualify for this multiple myeloma clinical trial in Greeley, CO
If you're searching for multiple myeloma treatment options in Greeley, CO, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Greeley research site is actively enrolling participants for this clinical trial. You'll receive care from experienced multiple myeloma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.